

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 April 2023 (06.04.2023)



(10) International Publication Number
WO 2023/056440 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/713 (2006.01)
C07H 21/00 (2006.01) A61K 31/7115 (2006.01)
A61P 9/10 (2006.01) A61K 31/7125 (2006.01)

(21) International Application Number:

PCT/US2022/077381

(22) International Filing Date:

30 September 2022 (30.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/251,571	01 October 2021 (01.10.2021)	US
63/252,554	05 October 2021 (05.10.2021)	US
63/270,504	21 October 2021 (21.10.2021)	US
63/283,175	24 November 2021 (24.11.2021)	US
63/287,969	09 December 2021 (09.12.2021)	US

(71) Applicant: ADARX PHARMACEUTICALS, INC.

[US/US]; 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).

(72) Inventors: LI, Zhen; c/o ADARx Pharmaceuticals, Inc.,

5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).
ZHU, Rui; c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).
ZHOU, Zhiqing (Joel); c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).
FULTZ, Kimberly; c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).
STUDER, Sean; c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).

(74) Agent: BOWLER, Joseph, M. et al.; Wolf, Greenfield &

Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PREKALLIKREIN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.

WO 2023/056440 A1